PatSnap/clinical-trial huggingface dataset:
Clinical trial NCT01131026: Efficacy and Safety Evaluation of Levofloxacin Triple Therapy for Helicobacter Pylori Eradication
Official title: A Monocentric, Open-label, Efficacy and Safety Evaluation Study of the Triple Therapy of 500 mg Levofloxacin, 1000 mg Amoxicillin and 30 mg Lansoprazole on Helicobacter Pylori Eradication in 60 Patients Infected With H. Pylori
Conditions: Helicobacter Pylori Infection
Summary: Today, although the triple treatment with clarithromycin accepted as the primary treatment for Helicobacter pylori infection eradication is well tolerated, the eradication has been decreased to 65 %. However, the eradication resulting from TRIOL treatment with levofloxacin is expected to be 75 % or higher. If the target results can be reached, it will be concluded that TRIOL treatment with levofloxacin will be an alternative to the triple treatment with clarithromycin as the primary treatment.
Interventions:
description: tablet, 500 mg, once a day for ten days
name: Levofloxacin
other_name: Floxilevo 500 mg Tablet
type: Drug
description: tablet, 1000 mg, once a day for ten days
name: Amoxicillin
other_name: Dentamax 1 gr Tablet
type: Drug
description: capsule, 30 mg, twice a day for ten days
name: Lansoprazole
other_name: Degastrol 30 mg Capsule
type: Drug
Study arms:
Sponsor: Deva Holding AS
Collaborators: Erciyes Üniversitesi
TNC Ilac Arastirma Gelistirme Danismanlik San. ve Tic. Ltd. Sti.
Drug name mappings:
name: 左氧氟沙星
lang: CN
name: Levofloxacin
lang: EN
name: レボフロキサシン水和物
lang: JP
name: 兰索拉唑
lang: CN
name: Lansoprazole
lang: EN
name: ランソプラゾール
lang: JP
name: 阿莫西林
lang: CN
name: Amoxicillin Trihydrate
lang: EN
name: アモキシシリン水和物
lang: JP
Clinical trial NCT00437684: Lopinavir/Ritonavir Monotherapy Versus Standard Highly Active Antiretroviral Therapy (HAART) in HIV/HCV Coinfected Patients Starting Treatment With Anti-Hepatitis C Virus (HCV) Therapy
Official title: A Pilot, Open Label, Multicenter, Randomized Clinical Trial on Lopinavir/Ritonavir-Monotherapy vs Lopinavir/Ritonavir Plus Selected Nucs, in HIV/HCV Coinfected Patients With Chronic Hepatitis C or Compensated Cirrhosis, Starting Treatment With Ribavirin and Pegylated Interferon
Conditions: HIV Infections
Hepatitis C
Summary: The purpose of this study is to evaluate if the combination of Lpv/r monotherapy and anti-HCV drugs does not match with additional toxicity induced by the association of HAART and Peg-IFN + ritonavir in HIV/HCV coinfected patients.
Secondary objective is to assess if Lpv/r monotherapy during HCV-treatment is associated with HIV efficacy versus optimized HAART.
Interventions:
description: 200/50 mg 2 cpr bid monotherapy
name: LPV/r
type: Drug
description: PEG-IFNa 2a 180 mcg/week
name: PEG-IFNa 2a
type: Drug
description: Ribavirin 1-1.2 g/day
name: Ribavirin
type: Drug
description: Nucleoside Reverse Transcriptase Inhibitors
name: NUCS
type: Drug
Study arms:
design_group_description: LPV/r: LPV/r monotherapy and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
design_group_title: A
design_group_type: Experimental
design_group_description: LPV/r+ selected NUCS and anti HCV drugs for 12 months. All the patients will be followed-up for six months after the end of anti-HCV drugs for the evaluation of Sustained Virological Response (SVR). At the end of the co-treatment for HCV/HIV, each subject will be treated for HIV infection according to physician decisions.As anti-HCV drugs the patients will receive PEG-IFNa 2a 180 mcg/week + Ribavirin 1-1.2 g/day .At the end of the third month of combined therapy, only patients who reach an early virological response will continue anti-HCV drugs.
design_group_title: B
design_group_type: Active Comparator
Sponsor: Ospedale San Raffaele Srl
Collaborators: Hoffmann-La Roche, Inc.
Abbott Laboratories
Drug name mappings:
name: 洛匹那韦/利托那韦
lang: CN
name: Lopinavir/Ritonavir
lang: EN
name: ロピナビル/リトナビル
lang: JP
name: 利巴韦林
lang: CN
name: Ribavirin
lang: EN
name: リバビリン
lang: JP
Clinical trial NCT05823311: Lenvatinib, Tislelizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
Official title: A Randomized, Double-blind, Multicenter Study of Lenvatinib, Temalizumab Combined with Gemcitabine and Cisplatin (GPLET) in the Treatment of Advanced Cholangiocarcinoma
Conditions: Advanced Cholangiocarcinoma
Summary: Cholangiocarcinoma (CCA) is a heterogeneous group of cancers arising from the epithelial cells of bile ducts. Because of highly aggressive malignancy, most of the patients are diagnosed at an advanced stage and lose the chance to undergo surgery.
As more effective and novel chemotherapy, targeted therapies, and immunotherapy become available, multiple treatments can be chosen for the patients with advanced CCA. Cytotoxic cell death during tumor chemotherapy triggers antigen release and induces strong anti-tumor effects of T cells. Tyrosine kinase inhibitors (TKI) can reduce the expression of PD-L1 and inhibit Treg cell infiltration, and together with immune checkpoint inhibitors, they can relieve tumor immunosuppressive microenvironment.
Therefore, the study aims to investigate the safety and efficacy of Lenvatinib, Tislelizumab combined with Gemcitabine plus Cisplatin (GPLET) in the treatment of advanced cholangiocarcinoma.
Interventions:
description: Intravenous injection: gemcitabine and cisplatin (CG) + tislelizumab； Oral administration: lenvatinib.
name: Lenvatinib, tislelizumab, gemcitabine and cisplatin
type: Drug
description: Intravenous injection: gemcitabine and cisplatin (CG) + placebo； Oral administration: placebo.
name: Gemcitabine and cisplatin
type: Drug
Study arms:
design_group_description: Intravenous injection: gemcitabine and cisplatin (CG)+ tislelizumab； Oral administration: lenvatinib.
design_group_title: GPLET (Lenvatinib, Tislelizumab Plus Gemcitabine and Cisplatin)
design_group_type: Experimental
design_group_description: Intravenous injection: gemcitabine and cisplatin (CG)+placebo； Oral administration: placebo.
design_group_title: CG (Gemcitabine and Cisplatin)
design_group_type: Placebo Comparator
Sponsor: The Second Affiliated Hospital Zhejiang University
Collaborators: The First Affiliated Hospital of Zhengzhou University
Drug name mappings:
name: 替雷利珠单抗
lang: CN
name: Tislelizumab
lang: EN
name: チスレリズマブ（遺伝子組換え）（JAN）
lang: JP
name: 顺铂
lang: CN
name: Cisplatin
lang: EN
name: シスプラチン
lang: JP
name: 吉西他滨
lang: CN
name: Gemcitabine
lang: EN
name: 甲磺酸仑伐替尼
lang: CN
name: Lenvatinib mesylate
lang: EN
name: レンバチニブメシル酸塩
lang: JP
Clinical trial NCT00022685: Epratuzumab in Treating Patients With Non-Hodgkin's Lymphoma
Official title: A Phase III Clinical Trial of Immunotherapy With Humanized LL2 IgG (Epratuzumab) in Patients With Low-Grade Follicular, B-Cell Non-Hodgkin's Lymphoma Refractory to Rituxan (Rituximab)
Conditions: Lymphoma
Summary: RATIONALE: Monoclonal antibodies such as epratuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells.
PURPOSE: Phase III trial to determine the effectiveness of epratuzumab in treating patients who have low-grade non-Hodgkin's lymphoma that has not responded to chemotherapy or rituximab.
Interventions:
name: epratuzumab
type: Biological
Study arms:
Sponsor: Jonsson Comprehensive Cancer Center
Collaborators: National Cancer Institute
Drug name mappings:
name: 依帕珠单抗
lang: CN
name: Epratuzumab
lang: EN
Clinical trial NCT00493974: Zileuton to Treat Adults With Chronic Obstructive Pulmonary Disease (The LEUKO Study)
Official title: Antileukotriene Therapy for COPD Exacerbations
Conditions: Pulmonary Disease, Chronic Obstructive
Summary: Chronic obstructive pulmonary disease (COPD) is a long-term lung disease that is caused by cigarette smoking or by breathing in other lung irritants, including pollution, dust, or chemicals. The purpose of this study is to evaluate the effectiveness of zileuton, a medication that is used to control asthma symptoms, at reducing the length of a hospital stay for adults who are hospitalized for a COPD exacerbation, or worsening of COPD symptoms.
Interventions:
description: Zyflo tablets, 600 mg, 4 times a day
name: Zileuton
other_name: Zyflo
type: Drug
description: Placebo 4 x daily
name: Placebo
other_name: Inactive Matching Placebo
type: Drug
Study arms:
design_group_description: Zileuton (Zyflo, 600 mg 4 times a day)
design_group_title: Zileuton
design_group_type: Active Comparator
design_group_description: Placebo
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: University of Minnesota
Collaborators: National Heart, Lung & Blood Institute
Drug name mappings:
name: 齐留通
lang: CN
name: Zileuton
lang: EN
Clinical trial NCT04210973: Comparison of Anyu Peibo With Placebo in Treatment of MDD in China
Official title: Efficacy and Safety Study of Anyu Peibo in the Treatment of Major Depressive Disorder(MDD): a Ⅲ Randomized, Double-Blind, Placebo-Paralleled, Multicenter Clinical Trial
Conditions: Major Depressive Disorder
Summary: The purpose of this study is to evaluate the efficacy and safety of Anyu Peibo Capsule comparing with placebo in the treatment of Chinese Patients with Depression.
Interventions:
description: Anyu Peibo Capsule, 0.8g twice per day, oral after breakfast and supper
name: Anyu Peibo
type: Drug
description: Placebo Capsule, twice per day, oral after breakfast and supper
name: Placebo
type: Drug
Study arms:
design_group_description: Anyu Peibo Capsule, oral, 0.8g twice per day
design_group_title: Anyu Peibo
design_group_type: Experimental
design_group_description: Placebo,oral, twice per day
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Shanghai Mental Health Center
Collaborators: Su Zhou YiHua Biotechnology Co. LTD
Drug name mappings:
name: 安郁沛勃胶囊
lang: CN
name: Anyu Peibo Capsule
lang: EN
Clinical trial NCT02194595: Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Official title: Preserving Beta-cell Function in Type 2 Diabetes With Exenatide and Insulin (PREVAIL)
Conditions: Type 2 Diabetes
Summary: Type 2 diabetes mellitus is a chronic metabolic disorder characterized by progressive deterioration in the function of the pancreatic beta-cells, which are the cells that produce and secrete insulin (the hormone primarily responsible for the handling of glucose in the body). The investigators propose a randomized controlled trial to determine whether combining basal insulin with a new medication called exenatide is a therapeutic strategy that can preserve beta-cell function early in the course of type 2 diabetes.
Interventions:
name: Basal insulin and exenatide
other_name: Basal insulin glargine
Exenatide
type: Drug
name: Basal insulin only
other_name: Basal insulin glargine
type: Drug
name: Basal insulin and bolus insulin
other_name: Basal insulin glargine
Pre-meal insulin lispro
type: Drug
Study arms:
design_group_description: Participants in this arm will undergo an 8-week course of treatment with exenatide and insulin glargine. Exenatide will be initiated at 5ug subcutaneous (sc) bid (before breakfast and before dinner) for the first 4 weeks, followed by 10ug bid for the next 4 weeks. Glargine sc injection at bedtime will be titrated to fasting glucose.
design_group_title: Basal insulin and exenatide
design_group_type: Experimental
design_group_description: Participants in this arm will undergo an 8-week course of treatment with glargine sc injection at bedtime, titrated to target fasting glucose.
design_group_title: Basal insulin only
design_group_type: Active Comparator
design_group_description: Participants in this arm will undergo an 8-week course of multiple daily insulin injection therapy, consisting of titrated basal insulin glargine at bedtime and insulin lispro before each meal.
design_group_title: Basal Insulin and bolus insulin
design_group_type: Active Comparator
Sponsor: Mount Sinai Hospital (Canada)
Collaborators: University of Toronto
Canadian Institutes of Health Research
Drug name mappings:
name: 艾塞那肽
lang: CN
name: Exenatide
lang: EN
name: エキセナチド
lang: JP
Clinical trial NCT00217022: Budesonide Versus Placebo for the Treatment of Lymphocytic Colitis
Official title: A Randomized, Double-Blind, Placebo Controlled Trial of Budesonide for the Treatment of Active Lymphocytic Colitis
Conditions: Lymphocytic Colitis
Diarrhea
Summary: Patients will receive budesonide or placebo for the treatment of active lymphocytic colitis. This study includes stool collections, blood draws, weekly questionnaires and a sigmoidoscopy. The study hypothesis is that budesonide will be safe and effective compared with placebo for the treatment of diarrhea in lymphocytic colitis.
Interventions:
description: Placebo, 3 tablets daily
name: Placebo
type: Other
description: 9 mg daily (three tablets)
name: Budesonide
other_name: Entocort EC
type: Drug
Study arms:
design_group_description: 9 mg daily
design_group_title: Budesonide
design_group_type: Active Comparator
design_group_description: three tablets daily
design_group_title: Placebo
design_group_type: Placebo Comparator
Sponsor: Mayo Clinic
Collaborators: AstraZeneca PLC
National Center for Research Resources
Drug name mappings:
name: 布地奈德
lang: CN
name: Budesonide
lang: EN
name: ブデソニド
lang: JP
Clinical trial NCT00861250: Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT
Official title: Assessment of Molecular Remission by ASO-RQ-PCR Technique After Induction Treatment With Bortezomib-dexamethasone (Vel/Dex) Followed by HDT With ASCT
Conditions: Multiple Myeloma
Summary: The primary objective of this study is to determine the rate of molecular remissions (MolR) assessed by ASO-RQ-PCR technique after induction treatment with bortezomib and dexamethasone (Vel/Dex) prior to high-dose therapy with melphalan and autologous stem cell transplantation (HDT-ASCT), and after HDT-ASCT in patients with multiple myeloma.
Interventions:
description: Bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4, 9-12 in cycles 1- 2, then bortezomib 1,3mg/m2 iv days 1,4,8,11, dexamethasone 40mg/day days 1-4 in cycles 3-4, total number of cycles is 4, followed by HDT with ASCT
name: bortezomib + dexamethasone
other_name: VelcadeTM
type: Drug
Study arms:
design_group_title: Vel/Dex
design_group_type: Experimental
Sponsor: Tampere University Hospital
Collaborators: Helsinki University Central Hospital
Janssen-Cilag Ltd.
Turku University Hospital
Oulu University Hospital
Drug name mappings:
name: 硼替佐米
lang: CN
name: Bortezomib
lang: EN
name: ボルテゾミブ
lang: JP
name: 地塞米松
lang: CN
name: Dexamethasone
lang: EN
name: デキサメタゾン
lang: JP
Clinical trial NCT00802529: Transtympanic Gentamicin vs. Steroids in Refractory Meniere's Disease
Official title: Effectiveness of Transtympanic Steroids in Unilateral Ménière's Disease: a Randomised Controlled Double-Blind Trial
Conditions: Meniere's Disease
Summary: This trial aims to compare transtympanic steroids against the standard treatment (transtympanic gentamicin) in refractory unilateral Meniere's disease.
Interventions:
description: 2 transtympanic injections at interval of two weeks.
name: Methylprednisolone
type: Drug
description: 2 transtympanic injections at an interval of two weeks. If there is significant hearing loss before second injection, it will be replaced by normal saline in double blinded fashion.
name: Gentamicin
type: Drug
Study arms:
design_group_description: Steroid (Methylprednisolone)
design_group_title: Steroid (Methylprednisolone)
design_group_type: Experimental
design_group_description: Gentamicin
design_group_title: Gentamicin
design_group_type: Active Comparator
Sponsor: Imperial College London
Collaborators: Imperial College Healthcare NHS Trust
The Medical Research Council
Drug name mappings:
name: 甲泼尼龙
lang: CN
name: Methylprednisolone
lang: EN
name: メチルプレドニゾロン
lang: JP
Clinical trial NCT01327495: PROS-2 Dose Response Effects of Exogenous Testosterone on the Prostate
Official title: Dose Response Effects of Exogenous Testosterone on the Prostate and Comparison With Effects on Body Composition (Short Title: PROS-2)
Conditions: Healthy
Summary: The investigators will conduct a three-month, randomized, placebo-controlled trial comparing the effects of increasing doses of androgen supplementation with Testosterone (T) gel on the prostate in healthy men who are treated with acyline to block gonadal androgen production.
Interventions:
description: Placebo acyline subcutaneous injection every 2 weeks
name: placebo acyline
other_name: placebo
type: Other
description: daily placebo testosterone gel applied transdermally x 12 weeks
name: placebo gel
other_name: placebo
type: Other
description: testosterone 1% gel 1.25 g daily applied transdermally x 12 weeks
name: Testosterone 1% gel 1.25 g
other_name: Androgel
type: Drug
description: Testosterone 1% gel 2.5 g daily applied transdermally x 12 weeks
name: Testosterone 1% gel 2.5 g
other_name: Androgel
type: Drug
description: Testosterone 1% gel 5.0 g daily applied transdermally x 12 weeks
name: Testosterone 1% gel 5.0 g
other_name: Androgel
type: Drug
description: Testosterone 1% gel 10 g daily applied transdermally x 12 weeks
name: testosterone 1% gel 10 g
other_name: Androgel
type: Drug
description: Testosterone 1% gel 15 g daily applied transdermally x 12 weeks
name: testosterone 1% gel 15 g
other_name: Androgel
type: Drug
description: 300 ug/kg subcutaneous injection every 2 weeks
name: Acyline
other_name: GNRH antagonist
type: Drug
Study arms:
design_group_description: Placebo acyline every 2 weeks for two weeks + daily placebo gel x 12 weeks
design_group_title: Arm 1: Placebo
design_group_type: Placebo Comparator
design_group_description: Acyline (300µg/kg every two weeks) + testosterone 1% gel 1.25 g daily x 12 weeks
design_group_title: Arm 2:1.25g Testosterone
design_group_type: Active Comparator
design_group_description: Acyline (300µg/kg every two weeks) + testosterone 1% gel 2.5 g daily x 12 weeks
design_group_title: Arm 3: 2.5g Testosterone
design_group_type: Active Comparator
design_group_description: Acyline (300µg/kg every two weeks) + testosterone 1% gel 5.0 g daily x 12 weeks
design_group_title: Arm 4: 5g Testosterone
design_group_type: Active Comparator
design_group_description: Acyline (300µg/kg every two weeks) + testosterone 1% gel 10 g daily x 12 weeks
design_group_title: Arm 5: 10g Testosterone
design_group_type: Active Comparator
design_group_description: Acyline (300µg/kg every two weeks) + testosterone 1% gel 15 g daily x 12 weeks
design_group_title: Arm 6: 15g Testosterone
design_group_type: Active Comparator
Sponsor: University of Washington
Collaborators: National Institute on Aging
National Institutes of Health
Drug name mappings:
name: 睾酮
lang: CN
name: Testosterone
lang: EN
name: Acyline
lang: EN
Clinical trial NCT02654730: Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia
Official title: Evaluation of the Safety of Primaquine in Combination With Dihydroartemisinin-piperaquine in G6PD Deficient Males in The Gambia
Conditions: Malaria
Summary: The purpose of this study is to evaluate the tolerability and safety of increasing doses of primaquine in combination with dihydroartemisinin-piperaquine in G6PD deficient males.
Interventions:
description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days
name: Dihydroartemisinin-piperaquine (DHAP) administered to G6PD deficient
other_name: Eurartesim
type: Drug
description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
name: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD deficient
type: Drug
description: G6PD deficient participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
name: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD deficient
type: Drug
description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.25mg/kg of primaquine on the first day of DHAP treatment.
name: Dihydroartemisinin-piperaquine (DHAP) + 0.25 mg/kg primaquine administered to G6PD normal
type: Drug
description: G6PD normal participants will be treated with dihydroartemisinin-piperaquine (Eurartesim®; Sigma Tau) administered as 3 tablets (40mg PPQ, 320mg DHA) in a once daily regimen for three days in combination with a single dose of 0.4mg/kg of primaquine on the first day of DHAP treatment.
name: Dihydroartemisinin-piperaquine (DHAP) + 0.4 mg/kg primaquine administered to G6PD normal
type: Drug
Study arms:
design_group_title: G6PD deficient 0.25 mg/kg PQ + DHAP
design_group_type: Experimental
design_group_title: G6PD deficient 0.4 mg/kg PQ + DHAP
design_group_type: Experimental
design_group_title: G6PD deficient DHAP only
design_group_type: Active Comparator
design_group_title: G6PD normal 0.25 mg/kg PQ + DHAP
design_group_type: Active Comparator
design_group_title: G6PD normal 0.4 mg/kg PQ + DHAP
design_group_type: Active Comparator
Sponsor: London School of Hygiene & Tropical Medicine
Collaborators: The Medical Research Council
Drug name mappings:
name: 双氢青蒿素哌喹
lang: CN
name: Piperaquine tetraphosphate/Artenimol
lang: EN
name: 磷酸伯氨喹
lang: CN
name: Primaquine Phosphate
lang: EN
name: プリマキンリン酸塩
lang: JP
Clinical trial NCT00414128: Clinical Trial of Mycophenolate Versus Cyclophosphamide in ANCA Vasculitis
Official title: A Randomised Clinical Trial of Mycophenolate Mofetil Versus Cyclophosphamide for Remission Induction in ANCA Associated Vasculitis.
Conditions: Vasculitis
Summary: The purpose of this study is to investigate whether mycophenolate mofetil is effective as treatment for new cases of ANCA associated vasculitis.
Interventions:
description: 2-3g/day for 3-6 months, in tablet, capsule or liquid form
name: mycophenolate mofetil
other_name: Cellcept
type: Drug
description: intravenous cyclophosphamide, 15mg/kg with dose reductions according to age and renal function, for 3-6 months (6-10 doses total)
name: cyclophosphamide
other_name: cytoxan
type: Drug
Study arms:
design_group_description: Mycophenolate mofetil for 3-6 months until in stable remission, dose 2-3g/day
design_group_title: mycophenolate mofetil
design_group_type: Experimental
design_group_description: pulsed intravenous cyclophosphamide 15mg/kg for 3-6 months (6-10 doses)until in stable remission
design_group_title: cyclophosphamide
design_group_type: Active Comparator
Sponsor: Cambridge University Hospitals NHS Foundation Trust
Collaborators: Corden Pharma Fribourg SA
Aspreva Pharmaceuticals Corp.
Drug name mappings:
name: 吗替麦考酚酯
lang: CN
name: Mycophenolate Mofetil
lang: EN
name: ミコフェノール酸 モフェチル
lang: JP